Innate Pharma (IPH) — Working Capital to Net Assets Ratio
Innate Pharma (IPH) has a Working Capital to Net Assets ratio of -46.4% as of December 2025. Working capital of €10.06 Million (current assets of €46.71 Million minus current liabilities of €36.65 Million) is measured against net assets of €-21.70 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See IPH days of operational coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Innate Pharma Working Capital to Net Assets (2005–2025)
This chart shows how Innate Pharma's Working Capital to Net Assets ratio has evolved across 21 annual periods from 2005 to 2025. As of December 2025, the ratio stands at -46.4%, reflecting working capital of €10.06 Million against net assets of €-21.70 Million EUR. For the complete balance sheet picture, see Innate Pharma balance sheet assets.
Annual Working Capital to Net Assets for Innate Pharma (2005–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Innate Pharma from 2005 to 2025, covering 21 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check IPH asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -46.4% | €10.06 Million | €-21.70 Million | €46.71 Million | €36.65 Million | ▼ -643.6 pp |
| 2024 | 597.2% | €52.76 Million | €8.83 Million | €85.74 Million | €32.98 Million | ▲ +388.4 pp |
| 2023 | 208.8% | €108.38 Million | €51.90 Million | €148.01 Million | €39.64 Million | ▲ +26.9 pp |
| 2022 | 181.9% | €98.49 Million | €54.15 Million | €139.83 Million | €41.34 Million | ▲ +127.6 pp |
| 2021 | 54.3% | €58.37 Million | €107.44 Million | €138.26 Million | €79.89 Million | ▼ -26.9 pp |
| 2020 | 81.2% | €126.64 Million | €155.97 Million | €173.33 Million | €46.69 Million | ▲ +27.9 pp |
| 2019 | 53.3% | €115.78 Million | €217.42 Million | €237.60 Million | €121.82 Million | ▼ -20.2 pp |
| 2018 | 73.5% | €122.91 Million | €167.24 Million | €319.64 Million | €196.74 Million | ▼ -0.5 pp |
| 2017 | 74.0% | €63.61 Million | €85.96 Million | €137.52 Million | €73.91 Million | ▼ -104.3 pp |
| 2016 | 178.3% | €153.64 Million | €86.17 Million | €230.08 Million | €76.44 Million | ▼ -88.1 pp |
| 2015 | 266.4% | €191.96 Million | €72.07 Million | €252.13 Million | €60.16 Million | ▲ +174.5 pp |
| 2014 | 91.8% | €68.54 Million | €74.63 Million | €79.31 Million | €10.78 Million | ▼ -7.6 pp |
| 2013 | 99.5% | €40.07 Million | €40.29 Million | €49.35 Million | €9.28 Million | ▼ -10.2 pp |
| 2012 | 109.7% | €25.63 Million | €23.36 Million | €41.00 Million | €15.36 Million | ▼ -31.1 pp |
| 2011 | 140.8% | €37.48 Million | €26.62 Million | €52.98 Million | €15.49 Million | ▲ +41.4 pp |
| 2010 | 99.3% | €33.29 Million | €33.52 Million | €40.66 Million | €7.37 Million | ▼ -0.4 pp |
| 2009 | 99.7% | €47.00 Million | €47.12 Million | €56.27 Million | €9.27 Million | ▲ +4.5 pp |
| 2008 | 95.3% | €39.39 Million | €41.34 Million | €52.21 Million | €12.82 Million | ▲ +4.5 pp |
| 2007 | 90.8% | €45.05 Million | €49.61 Million | €55.59 Million | €10.55 Million | ▼ -5.4 pp |
| 2006 | 96.2% | €54.24 Million | €56.37 Million | €64.27 Million | €10.04 Million | ▲ +1.8 pp |
| 2005 | 94.4% | €18.95 Million | €20.07 Million | €21.21 Million | €2.26 Million | — |